Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders\n\n\n\n TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce today the results of its annual general and special meeting of shareholders, held on Friday, September 26, 2025 in person at 801-1 Adelaide Street East, Toronto, ON M5C 2V9 (“\n \n AGSM\n \n ”).\n \n\n There were shareholders represented in person or by proxy at the AGSM holding 12 class A multiple voting shares (the “\n \n Class A Multiple Voting Shares\n \n ”) and 1,769,228 class B subordinate voting shares (the “\n \n Class B Subordinate Voting Shares\n \n ”), representing 100% and 46.352% of the votes attached to the Class A Multiple Voting Shares and Class B Subordinate Voting Shares, respectively, with each Class A Multiple Voting Share entitling the holders thereof to 276,660 votes on all matters.\n \n\n Each nominee listed in the Company’s management information circular dated August 14, 2025, was elected as a director of the Company. Each director will serve until the next annual meeting of shareholders or until his or her successor is duly elected or appointed. The results of which were as follows:\n \n\n\n\n\n Nominee\n \n\n\n\n Votes For\n \n\n\n\n % Votes For\n \n\n\n\n\n Anthony Durkacz\n \n\n 4,200,352\n \n\n 99.809%\n \n\n\n\n\n\n Zeeshan Saeed\n \n\n 4,194,933\n \n\n 99.680%\n \n\n\n\n\n\n Dr. Lakshmi P. Kotra\n \n\n 4,198,379\n \n\n 99.833%\n \n\n\n\n\n\n Adnan Bashir\n \n\n 4,192,338\n \n\n 99.692%\n \n\n\n\n\n\n Terry Lynch\n \n\n 4,197,772\n \n\n 99.819%\n \n\n\n\n\n\n Michael (Zappy) Zapolin\n \n\n 4,197,828\n \n\n 99.820%\n \n\n\n\n\n\n Dr. Eric Hoskins\n \n\n 4,198,027\n \n\n 99.825\n \n %\n \n\n\n\n\n\n\n\n\n\n In addition, at the AGSM, the shareholders also: (i) re-appointed MNP LLP as the Company’s auditor (the “\n \n Auditor\n \n ”) and ...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B